ENTA Latest Press Releases

-- October 13, 2026 --

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek 2026 Business Wire 7:00 AM

-- September 1, 2026 --

Enanta Pharmaceuticals to Participate in September Investor Conferences Business Wire 7:00 AM

-- August 10, 2026 --

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 Business Wire 4:01 PM

-- June 23, 2026 --

Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Business Wire 5:10 AM

-- June 18, 2026 --

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV) Business Wire 7:00 AM

-- May 28, 2026 --

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference Business Wire 7:00 AM

Market Data Delayed 15 Minutes